News
Genetic testing firm 23andMe is set to be acquired by drug company Regeneron Pharmaceuticals following its bankruptcy in March, the companies announced on Monday, May 19. Regeneron purchased the ...
She regularly appears on CBS News 24/7 to discuss her reporting. Regeneron has agreed to buy 23andMe, the once buzzy genetic testing company, out of bankruptcy for $256 million under a court ...
Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D, but the benefits are years away and the risks are immediate. Eylea franchise revenues dropped 26% year-over-year as ...
Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies insisted the sensitive genetic data provided to 23andMe by 15 million ...
Regeneron said Monday it will “prioritize the privacy, security and ethical use” of the personal DNA data from about 15 million people in a $256 million deal to acquire assets of bankrupt ...
Regeneron Pharmaceuticals said Monday it will acquire 23andMe’s DNA testing business and most of its assets out of bankruptcy and pledged to continue offering the popular consumer service and ...
Regeneron Pharmaceuticals, a biotechnology company with a long history of large-scale genetics research, plans to buy DNA testing firm 23andMe out of bankruptcy, announcing Monday it was named the ...
Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...
Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Regeneron said it will comply with 23andMe’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback